
Spectral Medical ( ($TSE:EDT) ) has issued an update. Spectral Medical is a Phase 3 biomedical company developing Toraymyxin™ (PMX), a therapeutic hemoperfusion device designed to remove endotoxin from the
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| EDTXF | Spectral Medical | 0.73 | -0.23 | -24.29% |
| Name | Price | % Change | |
|---|---|---|---|
| $0.73 | -24.29% |

Spectral Medical ( ($TSE:EDT) ) has issued an update. Spectral Medical is a Phase 3 biomedical company developing Toraymyxin™ (PMX), a therapeutic hemoperfusion device designed to remove endotoxin from the

Spectral Medical ( ($TSE:EDT) ) has issued an announcement. Spectral Medical advanced the U.S. regulatory review of PMX during the third quarter, including an in-person FDA 100-Day Meeting. The agency’s

Spectral Medical (Edtxf) (EDTXF) is scheduled to report 3rd quarter earnings on 11/06/2026. Regarding Q3 estimates, Wall Street analysts expect Spectral Medical (Edtxf) to post earnings of -C$0.01 per share.

Spectral Medical ( ($TSE:EDT) ) has provided an update. Spectral Medical reported that the second quarter of 2026 marked a key inflection point as it submitted and successfully filed its

Spectral Medical (Edtxf) (EDTXF) is scheduled to report 2nd quarter earnings on 08/07/2026. Regarding Q2 estimates, Wall Street analysts expect Spectral Medical (Edtxf) to post earnings of -C$0.01 per share.

Spectral Medical ( ($TSE:EDT) ) has shared an announcement. Spectral Medical reported its fourth quarter and full-year 2025 results alongside a corporate update that underscored major clinical and regulatory progress

An announcement from Spectral Medical ( ($TSE:EDT) ) is now available. Spectral Medical and Vantive reported that full results from the Phase 3 Tigris trial of Polymyxin B Hemoadsorption in

Spectral Medical (Edtxf) (EDTXF) is scheduled to report 4th quarter earnings on 03/26/2026. Regarding Q4 estimates, Wall Street analysts expect Spectral Medical (Edtxf) to post earnings of -C$0.01 per share.

Spectral Medical ( ($TSE:EDT) ) has shared an announcement. Spectral Medical has delayed the timing of its Premarket Approval submission to the U.S. Food and Drug Administration for its PMX-20R

Spectral Medical (Edtxf) ( ($EDTXF) ) has released its Q3 earnings. Here is a breakdown of the information Spectral Medical (Edtxf) presented to its investors. Spectral Medical Inc. is a
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | May 31, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 19, 2027TBA | $213.44M | $-0.01 | $260.06K | -0.04 | -796.15 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.